David J Einstein - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

David J Einstein

Showing results (51-60 of 54) with videos related to

Pageof 6

Sort By:

You have reached the last page of results.This site can display upto 54 results.

Nature Communications|May 28, 2025

BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stressAndreas Varkaris, Keshan Wang, Mannan Nouri, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2025

Accelerating Drug Development in Hormone-Naïve Prostate Cancer Through Multi-Modal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical TrialDeaglan McHugh, Matthew Dallos, Min Yuen Teo, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2025

National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design ConsiderationsDavid J Einstein, Melissa L Abel, Jeanny B Aragon-Ching, et al.

Nature Cancer|April 26, 2021

EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancerKatherine L Morel, Anjali V Sheahan, Deborah L Burkhart, et al.

Pageof 6

Search research articles

Showing results (51-60 of 54) with videos related to

Sort By:

Pageof 6

You have reached the last page of results.This site can display upto 54 results.

Nature Communications|May 28, 2025

BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stressAndreas Varkaris, Keshan Wang, Mannan Nouri, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2025

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2025

National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design ConsiderationsDavid J Einstein, Melissa L Abel, Jeanny B Aragon-Ching, et al.

Nature Cancer|April 26, 2021

EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancerKatherine L Morel, Anjali V Sheahan, Deborah L Burkhart, et al.

Pageof 6